AlphaCentric Advisors’s Immunovant IMVT Stock Holding History

AlphaCentric Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$415K	Buy	+12,276	New	+$484K	0.37%	86
2024 Q4	–	Sell	-35,000	Closed	-$998K	–	249
2024 Q3	$998K	Sell	35,000 -1,500	-4%	-$44.2K	0.74%	47
2024 Q2	$964K	Sell	36,500 -1,500	-4%	-$42.7K	0.71%	50
2024 Q1	$1.23M	Hold	38,000	–	–	0.74%	53
2023 Q4	$1.6M	Hold	38,000	–	–	1.07%	31
2023 Q3	$1.46M	Buy	+38,000	New	+$859K	0.83%	40
2021 Q1	–	Sell	-2,150	Closed	-$99K	–	216
2020 Q4	$99K	Hold	2,150	–	–	0.04%	134
2020 Q3	$76K	Buy	2,150 +1,500	+231%	+$45.1K	0.04%	80
2020 Q2	$16K	Buy	+650	New	+$13.9K	0.01%	126

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

AlphaCentric Advisors's IMVT Position: Q3 2026 in Review

AlphaCentric Advisors opened a new position in Immunovant (IMVT) in Q3 2026: 12,276 shares worth $415K. The stake represents 0.37% of the portfolio and ranks #86 among its holdings. This is a return to the name: AlphaCentric Advisors previously reported a position in IMVT as recently as Q3 2024.

AlphaCentric Advisors first reported a position in IMVT in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.6M in Q4 2023. 160 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

AlphaCentric Advisors held 12,276 shares of Immunovant worth $415K as of Q3 2026.
Immunovant was a new AlphaCentric Advisors position in Q3 2026.
Immunovant made up 0.37% of AlphaCentric Advisors's portfolio in Q3 2026, its #86 holding.
AlphaCentric Advisors first reported a position in Immunovant in Q2 2020 and has held it in 9 quarters since.
AlphaCentric Advisors's Immunovant position peaked at $1.6M in Q4 2023.
160 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.